Your browser doesn't support javascript.
loading
Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia.
Vela, M; Corral, D; Carrasco, P; Fernández, L; Valentín, J; González, B; Escudero, A; Balas, A; de Paz, R; Torres, J; Leivas, A; Martinez-Lopez, J; Pérez-Martínez, A.
Afiliación
  • Vela M; Translational Research in Pediatric Oncology, Hematopoietic Transplantation & Cell Therapy, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain. Electronic address: maria.vela@idipaz.es.
  • Corral D; Pediatric Hemato-Oncology Unit, Hospital Universitario La Paz, Madrid, Spain. Electronic address: dolorescorralsanchez@gmail.com.
  • Carrasco P; Molecular Pediatric Oncology Unit, Institute of Medical and Molecular Genetics (INGEMM), Hospital Universitario La Paz, Madrid, Spain. Electronic address: mpilar.carrasco.sspa@juntadeandalucia.es.
  • Fernández L; H12O-CNIO Hematological Malignancies Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. Electronic address: lvfernandez@cnio.es.
  • Valentín J; Translational Research in Pediatric Oncology, Hematopoietic Transplantation & Cell Therapy, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain. Electronic address: jaime.valentin.quiroga@idipaz.es.
  • González B; Pediatric Hemato-Oncology Unit, Hospital Universitario La Paz, Madrid, Spain. Electronic address: berta.gonzalez@salud.madrid.org.
  • Escudero A; Molecular Pediatric Oncology Unit, Institute of Medical and Molecular Genetics (INGEMM), Hospital Universitario La Paz, Madrid, Spain. Electronic address: adela.escudero@salud.madrid.org.
  • Balas A; Histocompatibility, Transfusion Center of the Autonomous Community of Madrid, Spain. Electronic address: abalas.trans@salud.madrid.org.
  • de Paz R; Hematology Department, Hospital Universitario La Paz, Madrid, Spain. Electronic address: mraquelde.paz@salud.madrid.org.
  • Torres J; Clinical Immunology Department, Hospital Universitario La Paz, Madrid, Spain. Electronic address: juan.torres@salud.madrid.org.
  • Leivas A; Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain; H12O-CNIO Hematological Malignancies Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain. Electronic address: aleivas@h12o.es.
  • Martinez-Lopez J; Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain; H12O-CNIO Hematological Malignancies Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain. Electronic address: jmarti01@ucm.es.
  • Pérez-Martínez A; Translational Research in Pediatric Oncology, Hematopoietic Transplantation & Cell Therapy, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain; Pediatric Hemato-Oncology Unit, Hospital Universitario La Paz, Madrid, Spain. Electronic address: aperezmartinez@salud.madrid.org.
Cancer Lett ; 422: 107-117, 2018 05 28.
Article en En | MEDLINE | ID: mdl-29477379
Primary refractory or relapsed pediatric leukemia yield significant morbidity and mortality, with long-term survival rates <40%. Here we present a post-hoc analysis assessing safety and efficacy of infusing activated and expanded Natural Killer cells (NKAE) from haploidentical donors in patients from 2 clinical trials. In total, 18 children, adolescents and young adults with relapse or refractory acute leukemia were treated with two cycles of rescue chemotherapy followed by fresh NKAE cells infusions and low doses of IL-2. The overall response rate, complete remission achievement at the end of the study, was 72% (13 of 18). We infused 52 NKAE cell products containing a median of 6.76 × 106 NK cells/kg (0.7-34.16) and 0.49 × 106 T cells/kg (0-11). All infusions were well tolerated with no graft versus host disease nor other serious adverse events. Among the 14 patients who completed treatment, 4 of them are alive and leukemia-free more than 750 days post-transplant. We conclude that infusion of fresh NKAE cell therapy is feasible and safe in heavily pretreated pediatric population, and should be further investigated in advanced-phase clinical trials as well as a consolidation therapy to decrease relapse in patients with high-risk leukemia. TRIALS REGISTRATION: Registered at www.clinicaltrials.gov as NCT01944982 and NCT02074657.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Células Asesinas Naturales / Leucemia Mieloide Aguda / Leucemia-Linfoma Linfoblástico de Células Precursoras B / Interleucina-15 / Leucemia-Linfoma Linfoblástico de Células T Precursoras / Recurrencia Local de Neoplasia Límite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Cancer Lett Año: 2018 Tipo del documento: Article Pais de publicación: Irlanda
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Células Asesinas Naturales / Leucemia Mieloide Aguda / Leucemia-Linfoma Linfoblástico de Células Precursoras B / Interleucina-15 / Leucemia-Linfoma Linfoblástico de Células T Precursoras / Recurrencia Local de Neoplasia Límite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Cancer Lett Año: 2018 Tipo del documento: Article Pais de publicación: Irlanda